Beta Drugs LtdQ1 FY23Pharmaceuticals & Biotechnology

Beta Drugs Ltd

Q1 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→Beta Drugs Limited targets a continuous growth rate of 25%-30% CAGR over the next 2-3 years, maintaining the current trajectory.
→By FY ‘25 and FY ‘26, major growth drivers will be exports, own brand sales, and API business.
→The company plans to double sales in the next three years, targeting INR450 crores revenues.
→Export business growth is fueled by approvals and regulatory clearances in multiple countries.
→Own brands are expected to contribute around INR140-150 crores in sales within three years.
→The CDMO business will grow steadily at 10%-12%.
→Dermatology segment aims to reach break-even soon and grow significantly in 3-4 years.
→EBITDA margins targeted to remain around 25%-26%, with potential upside.
→Management sees minimal risk factors; growth is supported by increased capacities and experienced young leadership.

Category 3

→Beta Drugs targets a 25%-30% consistent growth over the next 2-3 years, maintaining the trajectory of prior years.
→EBITDA margins are expected to cross around 25%-26%, with potential for even higher margins if conditions improve.
→Major growth drivers include export business, own brands (targeting INR140-150 crores in next three years), and API business both domestically and internationally.
→CDMO business expected to grow steadily at about 10%-15%, aligned with oncology market CAGR.
→Gross margins have improved significantly due to backward integration and innovation, from 39% to 43%.
→The company expects EBITDA and net profit to grow proportionally with revenue, supported by increased production capacity and new products.
→Employee costs and marketing expenses will rise but remain well-controlled relative to revenue growth.
→No major capex planned beyond internal maintenance and minor expansions, helping profitability remain stable.
→Management expresses confidence in achieving targets without major hurdles, emphasizing disciplined execution.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Beta Drugs Ltd and 1,400+ other companies.

→No current or future fundraising plans through debt or equity.
→The INR18 crores capex done in the last year was funded entirely from internal cash accruals.
→The company is currently debt-free with a positive net cash position of over INR3 crores.
→Management indicated no need for major capital expenditure over the next 2-3 years that would require external funding.
→Emphasis on leveraging internal resources and cash flows to fund growth and expansion.

→Beta Drugs Limited has secured partners in 12-15 Latin American countries, including Mexico and Colombia, and has completed business development activities there.
→The company has started receiving API export orders from countries like Algeria, Pakistan, Bangladesh, and Russia, with expectations of exporting to three to four countries in the next 1-1.5 months.
→The expected revenue from API exports for the current year is around INR 3 to 4 crores.
→The company is actively working on obtaining multiple regulatory approvals (such as Europe, Eurasia, and ANVISA) to expand its international exports and is targeting significant growth from these markets.
→They anticipate rapid growth from oncology-focused new drug delivery systems (NDDS) slated for launch in the next 1.5 years.
→Overall growth targets include doubling sales by FY ‘25-‘26, with major contributions expected from own brand sales, exports, and API business.

Yes

→Major expansion is behind, but continuous capital investment will occur for maintenance, adding instruments, and minor expansions (e.g., AHU additions). (Page 16)
→No large new facility expansions planned for next 2-3 years to achieve targets; mainly internal capex and maintenance ongoing. (Page 12, 16)
→Dermatology manufacturing setup planned within next 2 years with estimated capex around INR 20 crores, funded through internal cash flows. (Page 14)
→Last year internal capex was around INR 18 crores distributed among three companies; no external fund raising planned as investments are from internal accruals. (Page 12)
→Continuous process of minor capital additions expected as per evolving needs but no major new capex announced currently. (Page 16)

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Beta Drugs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Beta Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.